Risk Factors for Mortality and Ventricular Tachycardia in Patients With Repaired Tetralogy of Fallot: A Systematic Review and Meta-analysis.


Journal

The Canadian journal of cardiology
ISSN: 1916-7075
Titre abrégé: Can J Cardiol
Pays: England
ID NLM: 8510280

Informations de publication

Date de publication:
11 2020
Historique:
received: 26 11 2019
revised: 14 01 2020
accepted: 28 01 2020
pubmed: 18 5 2020
medline: 20 5 2021
entrez: 17 5 2020
Statut: ppublish

Résumé

Patients with repaired tetralogy of Fallot (rTOF) have increased risk for mortality, sudden cardiac death, and ventricular tachycardia (VT). The aim of this systematic review and meta-analysis is to offer an updated analysis of risk factors following significant changes in surgical and perioperative management. A meta-analysis based on the published literature between 2008 and 2018 was conducted. Endpoints were VT, cardiac mortality/VT, and all-cause mortality/VT. Studies with ≥100 patients and ≥10 events were included. Fifteen studies including 7218 patients (average age 27.5 years) were analyzed. Risk factors for VT included older age (per 1 year, odds ratio [OR]: 1.039; 95% confidence interval [CI]: 1.025-1.053), older age at corrective surgery (per 1 year, OR: 1.034; CI: 1.017-1.051), previous palliative shunt (OR: 3.063; CI: 1.525-6.151), number of thoracotomies (OR: 1.416; CI: 1.249-1.604), longer QRS duration (per 1 ms, OR: 1.031; CI: 1.008-1.055), and at least moderate right-ventricular dysfunction (OR: 2.160; CI_ 1.311-3.560). Additional risk factors for cardiac death/VT were previous ventriculotomy (OR: 2.269; CI: 1.226-4.198), lower left-ventricular ejection fraction (per 1%, OR: 1.049; CI: 1.029-1.071), and higher right-ventricular end diastolic volume (per 1 mL/m The study highlights the importance of preservation of biventricular systolic function on late outcomes. Ventricular function appears to have a greater impact on outcomes than the severity of pulmonary regurgitation alone in this patient population.

Sections du résumé

BACKGROUND
Patients with repaired tetralogy of Fallot (rTOF) have increased risk for mortality, sudden cardiac death, and ventricular tachycardia (VT). The aim of this systematic review and meta-analysis is to offer an updated analysis of risk factors following significant changes in surgical and perioperative management.
METHODS
A meta-analysis based on the published literature between 2008 and 2018 was conducted. Endpoints were VT, cardiac mortality/VT, and all-cause mortality/VT. Studies with ≥100 patients and ≥10 events were included.
RESULTS
Fifteen studies including 7218 patients (average age 27.5 years) were analyzed. Risk factors for VT included older age (per 1 year, odds ratio [OR]: 1.039; 95% confidence interval [CI]: 1.025-1.053), older age at corrective surgery (per 1 year, OR: 1.034; CI: 1.017-1.051), previous palliative shunt (OR: 3.063; CI: 1.525-6.151), number of thoracotomies (OR: 1.416; CI: 1.249-1.604), longer QRS duration (per 1 ms, OR: 1.031; CI: 1.008-1.055), and at least moderate right-ventricular dysfunction (OR: 2.160; CI_ 1.311-3.560). Additional risk factors for cardiac death/VT were previous ventriculotomy (OR: 2.269; CI: 1.226-4.198), lower left-ventricular ejection fraction (per 1%, OR: 1.049; CI: 1.029-1.071), and higher right-ventricular end diastolic volume (per 1 mL/m
CONCLUSIONS
The study highlights the importance of preservation of biventricular systolic function on late outcomes. Ventricular function appears to have a greater impact on outcomes than the severity of pulmonary regurgitation alone in this patient population.

Identifiants

pubmed: 32416063
pii: S0828-282X(20)30059-3
doi: 10.1016/j.cjca.2020.01.023
pii:
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1815-1825

Informations de copyright

Copyright © 2020 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Mathias Possner (M)

Heart Institute, Cincinnati Children`s Hospital Medical Center, Cincinnati, Ohio, USA; University of Cincinnati College of Medicine, Department of Pediatrics, Cincinnati, Ohio, USA.

Stephanie Y Tseng (SY)

Heart Institute, Cincinnati Children`s Hospital Medical Center, Cincinnati, Ohio, USA; University of Cincinnati College of Medicine, Department of Pediatrics, Cincinnati, Ohio, USA.

Fares Alahdab (F)

Mayo Evidence-based Practice Center, Mayo Clinic, Rochester, Minnesota, USA.

Jouke P Bokma (JP)

Department of Cardiology, Academic Medical Center Amsterdam, The Netherlands.

Adam M Lubert (AM)

Heart Institute, Cincinnati Children`s Hospital Medical Center, Cincinnati, Ohio, USA; University of Cincinnati College of Medicine, Department of Pediatrics, Cincinnati, Ohio, USA.

Paul Khairy (P)

Department of Cardiology, Montréal Heart Institute, Université de Montréal, Montréal, Canada.

M Hassan Murad (MH)

Mayo Evidence-based Practice Center, Mayo Clinic, Rochester, Minnesota, USA.

Walid Ben Ali (W)

Division of Cardiac Surgery, CHU-ME Sainte Justine and the Montréal Heart Institute, Université de Montréal, Montréal, Canada.

Larry J Prokop (LJ)

Mayo Clinic Libraries, Mayo Clinic, Rochester, Minnesota, USA.

Richard J Czosek (RJ)

Heart Institute, Cincinnati Children`s Hospital Medical Center, Cincinnati, Ohio, USA; University of Cincinnati College of Medicine, Department of Pediatrics, Cincinnati, Ohio, USA.

Gruschen R Veldtman (GR)

Heart Institute, Cincinnati Children`s Hospital Medical Center, Cincinnati, Ohio, USA; University of Cincinnati College of Medicine, Department of Pediatrics, Cincinnati, Ohio, USA; Adult Congenital Heart Disease, Heart Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

Tarek Alsaied (T)

Heart Institute, Cincinnati Children`s Hospital Medical Center, Cincinnati, Ohio, USA; University of Cincinnati College of Medicine, Department of Pediatrics, Cincinnati, Ohio, USA. Electronic address: Tarek.Alsaied@cchmc.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH